Results 141 to 150 of about 14,247 (191)
Factors Influencing Herpes Zoster Vaccine Utilization Among Adults Aged 50 and Above Attending Primary Healthcare Center in Saudi Arabia: A Cross-Sectional Study. [PDF]
CureusAlmakhdob M, Selim M, Abdalrouf A.
europepmc +1 more source
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol. [PDF]
BMC Infect DisHentzien M +17 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The herpes zoster subunit vaccine
Expert Opinion on Biological Therapy, 2016Herpes zoster (HZ) causes severe pain and rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN).HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age related or other causes of decreased T cell immunity.
Anthony L Cunningham
exaly +3 more sources
Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status [PDF]
Human Vaccines and Immunotherapeutics, 2015 Options for managing herpes zoster (HZ)-related pain and complications have limited effectiveness, making HZ prevention through vaccination an important strategy. Limited data are available on HZ vaccine effectiveness against confirmed HZ and manifestations of HZ among vaccinated persons.
Mona Marin +2 more
exaly +3 more sources
Varicella–Zoster Vaccine for the Prevention of Herpes Zoster
New England Journal of Medicine, 2007A 64-year-old man in good general health presents to his internist for a routine examination. In a large clinical trial, the varicella–zoster vaccine reduced the incidence of herpes zoster by 51% and the incidence of postherpetic neuralgia by 67%. Should he receive this vaccine?
David W, Kimberlin, Richard J, Whitley
openaire +2 more sources